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Sentinel node biopsy (SNB) is an important step in melanoma staging and prognostication.
It is commonly performed for patients with intermediate thickness melanomas, based on
clinicopathological features. However, only 20–25% of patients eventually demonstrate
nodal involvement. The aim of this study was to evaluate whether tissue biomarkers with
links to melanoma biology, together with clinicopathological parameters, could aid in the pre-
diction of sentinel node involvement and improve selection of patients for SNB. In addition,
we examined the role of these clinical or biological markers in disease outcome.
Methods
We collected a case-control cohort of 140 intermediate thickness (Breslow 0,9–4,0mm)
melanoma patients with or without SNB involvement matched for age, gender, Breslow
thickness and location. From this cohort, we tested the predictive value of common clinico-
pathological parameters (ulceration, mitotic count and tumor regression) and FMNL-2, ezrin
and BRAF V600E immunoreactivity, for sentinel node involvement and survival. We further
analyzed the correlations in the superficial spreading melanoma subtype.
Results
Based on our case control analysis, of the markers, BRAF V600E status (p = 0.010) and
mitotic count (p = 0.036) correlated with SNB involvement. SNB status was a strong inde-
pendent prognosticator for recurrence free survival (RFS p<0.001), melanoma specific sur-
vival (MSS p = 0.000) and overall survival (OS p = 0.029). In the superficially spreading
melanoma subgroup, BRAF V600E positivity indicated poorer RFS (p = 0.039) and OS (p =
0.012). By combining the Breslow thickness, mitotic count and BRAF







Citation: Manninen AA, Gardberg M, Juteau S,
Ilmonen S, Jukonen J, Andersson N, et al. (2019)
BRAF immunohistochemistry predicts sentinel
lymph node involvement in intermediate thickness
melanomas. PLoS ONE 14(4): e0216043. https://
doi.org/10.1371/journal.pone.0216043
Editor: Nikolas K. Haass, University of Queensland
Diamantina Institute, AUSTRALIA
Received: September 13, 2018
Accepted: April 12, 2019
Published: April 30, 2019
Copyright: © 2019 Manninen et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files.
Funding: A.M. received grants from Helsinki
University research funds, Helsinki University
Hospital research funds for plastic surgery and
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immunohistochemistry, we identified a group of superficially spreading melanomas with an
excellent survival probability independent of SNB status.
Conclusions
These results demonstrate that BRAF immunohistochemistry could serve as a useful addi-
tion to a marker panel for selecting intermediate thickness melanoma patients for SNB.
Introduction
Cutaneous melanoma is a common malignant neoplasia with over 230 000 cases and 55 000
cancer deaths annually [1]. While death rates are projected to remain stable, melanoma inci-
dence and treatment costs are estimated to rise significantly through 2030 [2].
The dissemination and prognosis of melanoma is evaluated by the TNM-classification at
the time of diagnosis, assessing thickness (Breslow) and ulceration of the primary tumor (T),
lymph node involvement (N) and presence of distant metastases (M) [3]. According to TNM-
classification, tumors are categorized into four stages, where stage I and II are local, stage III
includes positive regional lymph nodes and stage IV has distant metastases. Melanoma prog-
nosis declines as the stage increases and in stage IV, the 5-year survival is only 15–20% [4]. At
present, sentinel node biopsy (SNB) has proven to be the most important prognostic factor for
melanoma specific survival and overall survival in patients with cutaneous melanoma thicker
than 1mm [5]. In several recommendations, SNB is performed for melanomas thicker than 0.9
mm. If the tumor is ulcerated, SNB may be performed even in thinner melanomas. Even
though uncommon, these superficial melanomas occasionally metastasize [6]. Standard of care
in the intermediate thickness (1.0–4.0 mm Breslow) melanoma includes radical excision of the
primary tumor and concomitant SNB. However, in this patient group, only 20–25% of patients
have affected sentinel lymph nodes. This means that up to five operations are needed to detect
a single lymph node positive patient [7]. There is a clear need for markers that would improve
the preoperative identification of sentinel lymph node positive/negative patients for targeting
individuals for SNB. Currently, such biomarkers have not been described.
In melanoma, the commonly activated oncogenic signaling pathways include MAPK (mito-
gen activated protein kinase) and the PI3K (phosphoinositide-3-OH kinase). Over-activation
of these pathways leads to increased cell proliferation and cancer cell survival [8]. Abnormal
activation is typically induced by oncogenic mutations. In melanomas, the most commonly
mutated oncogene is BRAF present in more than 50% of tumors [9]. Ninety percent of all acti-
vating BRAF mutations involve V600E substitution [10]. BRAF V600E increases the invasive
potential of melanoma cells, but the down-stream effectors are not well known [11].
Formins constitute a protein family with diverse actin-regulating and potentially pro-inva-
sive functions linked to formation of protrusions of lamellipodia at the cell migrating edge
[12]. The family includes two homologous members, formin-like protein 2 (FMNL2) and for-
min-like protein 3 (FMNL3). Previous studies have suggested that especially FMNL2 partici-
pates in melanoma cell invasion by driving elongation of actin filaments that constitute the
lamellipodia [13,14]. Gardberg et al. further analyzed the role of FMNL2 in invasive properties
of melanoma and melanoma outcome. In stage I-II melanoma patients, FMNL2 expression
was an independent predictor of survival together with melanoma thickness [15]. Interest-
ingly, in BRAF V600E mutant cells, the specific inhibitor vemurafenib, reduces FMNL2
expression [15]. Another actin-modulating protein involved in cell motility is ezrin, an adaptor
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protein that links the cytoskeleton to the plasma membrane [16]. Ezrin can promote tumor
invasion [17], and in various malignancies, including uveal melanoma, is significantly associ-
ated with outcome of the disease [18]. Ezrin expression is significantly higher in cutaneous
melanomas than in benign naevi and slightly higher expression levels are observed in meta-
static than in primary melanomas [19].
In the present study, our aim was to study potential predictors of sentinel node involvement
in a cohort of patients with intermediate thickness melanoma. Apart from the common clini-
copathological markers, we focused on BRAF V600E mutation detected by immunohis-
tochemistry and the immunoreactivity of FMNL2 and ezrin. In addition, we analyzed the
value of these markers in predicting disease outcome.
Methods
Patient cohort
The cohort consisted of patients with primary cutaneous melanoma operated at the Helsinki
University Hospital, Helsinki, Finland in 2007–2015, altogether 770 patients. Patient records
were reviewed, and 100 consecutive sentinel node biopsy—positive (SNB+) patients who met
the inclusion criteria were identified. The inclusion criteria were: positive sentinel node biopsy,
age during surgery (18–80 years), and intermediate thickness melanoma (Breslow 0.9–
4.0mm). Eighteen patients were excluded as the primary melanoma sample was missing. We
then selected a matching primary melanoma control group of patients whose sentinel node
was negative (SNB-). The case—control matching criteria were: patient age (+/- 5 years), same
anatomical location of the primary tumor (head and neck, trunk, upper limb or lower limb),
same sex and same melanoma thickness (+/- 0.2 mm). Patients whose primary melanoma
sample could not be recovered, were excluded from the study. This resulted in a final study
cohort of 70 SNB+ patients and 70 matching SNB-negative controls (N = 140).
All patients underwent wide local excision with histologically clear margins and SNB. If
sentinel node was found positive, the patients then underwent a secondary surgery for the
nodal basin, where the positive sentinel node was located (axillary clearance, groin evacuation
or neck dissection) according to clinical guidelines. Additional treatment included chemother-
apy for eighteen, radiotherapy for twenty-five and interferon for ten patients. In four cases, the
isolated limb perfusion was also used. The follow up was performed at the Department of Plas-
tic Surgery or at the Department of Oncology at Helsinki University Hospital. The final fol-
low-up date was defined as the date of the last follow-up visit or the date of death. Most recent
follow-up information was gathered from the medical records in August 2017. Median follow
up time was 5.1 years (range 2 months– 10 years). The cause of death was obtained from the
patient records and autopsy reports.
The Ethical Committee of Surgery of the University of Helsinki approved the use of the col-
lected tissue samples and associated clinical information for this study. Ethical committee
waived the need for informed consent from patients since no new specimen was collected.
Primary melanoma samples and SNB–specimens
New sections were cut from paraffin embedded specimens and stained with H&E. Relevant
pathological parameters (Breslow thickness, ulceration, mitotic count, tumor type, regression)
were evaluated by an experienced dermatopathologist. If the parameters differed from those
reported in the primary pathological report they were corrected. Sentinel nodes were sliced at
1 mm intervals and analyzed by routine H&E-staining and immunohistochemistry (IHC) (S-
100, HMB-45 and MART-1). From the sentinel node, S-100, MART-1 and HMB-45 IHC was
performed to identify metastatic cells. The size and location and possible multifocality of the
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metastasis were examined and reported. Isolated tumor cells (ITC) were also deemed positive
as a metastasis.
For BRAF V600E analysis, 3 um thick melanoma sections were stained with Ventana
Benchmark Ultra (Roche/Ventana, Tucson, AZ, USA). The protocol was based on heat-
induced epitope retrieval using standard pretreatment buffer CC1, 64 min/98˚C. The slides
were incubated with primary antibody, BRAF V600E that specifically recognizes the BRAF
V600E-mutation, (clone VE1, RTU, 790–4855, Roche/Ventana) for 44 min/36˚C. Antigen
detection was performed with biotin-free, three step multimer- based detection kit Optiview
(760–700, Roche/Ventana, Tucson, AZ, USA). The slides were dehydrated and mounted.
Hematoxylin staining was performed with slide staining instrument SAKURA TISSUE-TEK
PRISMA (Sakura Finetek Europe B.V., The Netherlands). For detailed description of the
method, see [20]. The stained specimens were then examined by two investigators (AM and
SJ) and labeled as positive or negative. The evaluators were blinded for the follow-up data, sen-
tinel node positivity and immunohistochemical results.
For ezrin analysis, sections were reacted with the primary murine IgG mAb to human ezrin
(clone 3C12, 1:250 dilution) [21], after deparaffinization and antigen retrieval with high pH
Target retrieval solution (Dako, Glostrup, DK). Endogenous peroxidase activity was blocked
with 3% hydrogen peroxidase, and nonspecific binding was prevented by using Novolink Pro-
tein block reagent. Immunoperoxidase staining was performed using a polymerized reporter
enzyme staining system (Novolink Polymer Detection System, Leica Biosystems, Newcastle,
GB) and ultraView Universal DAB Detection Kit (Ventana, Tucson, AZ) to visualize the
bound antibody. In control experiments, antibody diluent replaced the primary antibody. The
sections were counterstained with hematoxylin (Merck, Darmstadt, Germany) prior to mount-
ing. The samples were evaluated by two blinded examiners (AM and JJ) and in case of discrep-
ancy, a consensus was formed. Previously reported grading protocol was used where the
expression levels are graded as negative, weak, moderate or strong [22]. Examples of different
staining intensities are shown in Fig 1.
For FMNL2 analysis, specimens were stained with a rabbit anti-human FMNL2 polyclonal
antibody (Sigma-Aldrich Corporation, St Louis, MO) (1:500). The antibody validation and
staining procedures have been described previously [14]. We used the described intensity evalu-
ation, where the basal layer of skin keratinocytes served as an internal reference. Staining inten-
sity was divided into three categories: weak, moderate (similar to the basal keratinocytes) and
strong. Staining intensity was evaluated by two investigators (AM and MG) blinded for the fol-
low-up data and the sentinel node positivity. Examples of staining intensities are shown in Fig 1.
Statistical analysis
Categorical variables were characterized using frequencies and percent and in case of continu-
ous variables means, range of values was used. Cox’s regression analysis and chi-square tests
were used to determine the significant prognostic factors of disease free survival and recur-
rence free survival. Recurrence free survival was calculated from the date of the operation to
the date of first local, regional or distant recurrence or to the end of the follow up. Significant
explanatory variables in univariate analysis were included in the multivariate analysis. We also
included parameters that were not significant in our material but are known to be important
prognosticators in melanoma (i.e. ulceration and Breslow thickness). Cumulative percentages
for survival were estimated using Kaplan-Meier technique and differences between the stain-
ing groups were tested using log-rank test. The results of Cox’s regression analyses were quan-
tified by calculating hazard ratios with 95% confidence intervals (95% CI). P-values� 0.05
were regarded as statistically significant. All analyses were performed with SPSS-statistical
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program (IBM SPSS Statistics 24). All features of the individual tumors are presented in Sup-
porting information.
Results
The median age was 57.9 y (range 31–83 y). Of the 140 patients 72 were female and 68 were
male. Location of the melanoma was most often trunk area (N = 64), followed by lower limb
(N = 36), upper limb (N = 20) and head and neck (N = 20). The most common melanoma sub-
type was superficially spreading melanoma (N = 71), followed by nodular (N = 50) and acral
(N = 6). Thirteen cases could not be categorized. In the entire cohort, ulceration was present
in 32 (22.9%) primary melanomas (Table 1). We performed further division of the cohort in to
smaller subgroups according to melanoma location and pathological characteristics. The only
subgroup that remained sufficiently large for statistical analyses was the superficially spreading
melanoma group (N = 71).
We first analyzed, whether any of the clinicopathological parameters or tissue biomarkers
associated with sentinel node involvement. Mitotic count (�1/mm2 vs.<1/mm2) correlated
with sentinel node positivity (p = 0.036), whereas ulceration or tumor regression was not sig-
nificantly different between the SNB+ and SNB- melanomas (Table 1). Neither was there a dif-
ference in FMNL2 or ezrin expression between SNB+ and SNB- tumors (Table 2). On the
other hand, positive BRAF V600E immunoreactivity correlated with sentinel node involve-
ment (p = 0.013) in the entire cohort. When subjected to multivariate analysis with clinically
known prognostic markers of melanoma (Breslow thickness, ulceration, dermal mitosis level),
BRAF remained as a significant independent prognostic factor for SNB positivity. (Table 2).
Similar result was also seen in the subgroup of superficially spreading melanomas (p = 0.025).
Twenty-six patients died of melanoma (22 in the SNB+ group and 4 in the SNB- group). In
the whole cohort, overall survival was 72.9% and melanoma-specific survival 81.4%. As
expected, SNB+-group showed decreased overall survival (OS, 64.3% vs. 81.4%) and
Fig 1. Examples of Ezrin and FMNL2 immunohistochemistry results in primary cutaneous melanomas. A = weak cytoplasmic ezrin reactivity.
B = Moderate ezrin reactivity. C = Strong ezrin reactivity. D = Weak cytoplasmic FMNL2 reactivity. E = Moderate FMNL2 reactivity. F = Strong FMNL2
reactivity. Scalebar = 100μm.
https://doi.org/10.1371/journal.pone.0216043.g001
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melanoma-specific survival (MSS 68.6% vs. 94.3%). Recurrence rate was 30 (42.9%) in the
SNB+ group and 5 (7.1%) in the SNB- group. Recurrence free survival (RFS) was 3.96 years in
the SNB+ and 5.63 years in the SNB- group. Average time for a recurrence was 2.0 years. The
outcome information of the patient cohort is summarized in Table 1.
Sentinel node positivity was a significant prognostic factor for RFS (p<0.0001), MSS
(p<0.0001) and OS (p = 0.013) in univariate analysis. Kaplan-Meier survival curves are shown
in Fig 2. In this cohort of Breslow 0.9–4.0 mm melanomas, thickness of the primary tumor was
not associated with RFS, MSS or OS. Neither did ulceration of the primary tumor correlate
with RFS (p = 0.089), MSS (p = 0.127) or OS (p = 0.375), possibly due to the relatively small
number of ulcerated tumors (N = 32).
Table 1. Clinical and histopathological parameters of the patient cohort.
Age (years) Cohort SNB+ SNB- p-value HR (95%CI)
Mean 57.9
Median 57




Range 0.2-10 Matched Matched
Gender N (%)
Female 70 (50.0)
Male 70 (50.0) Matched Matched
Location
Trunk 64 (45.7)
Lower Limb 36 (25.7)
Upper Limb 20 (14.3)
Head and neck 20 (14.3) Matched Matched
Breslow thickness
� 1mm 17 (12.1)
1.01-2.0 mm 65 (46.4)
2.01-4.0 mm 58 (41.4) Matched Matched NS
Ulceration
Absent 108 (77.1) 54 (77.1) 54 (77.1) NS
Present 32 (22.9) 16 (22.9) 16 (22.9) NS
Dermal mitoses
<1/mm2 33 (23.6) 12 (17.1) 21 (30.0) NS
�1/mm2 107 (76.4) 58 (82.9) 49 (70.0) 0.015 1.91 (1.13-3.22)
Regression
Yes 7 (5.0) 3 (4.3) 4 (5.7) NS
No 133 (95.0) 67 (95.7) 66 (94.3) NS
Outcome
Alive 102 (72.9) 45 (64,3) 57 (81.4) 0.013 2.31 (1.12-4.45)
Died of melanoma 26 (18.6) 22 (31.4) 4 (5.7) <0.0001 7.16 (2.46-20.82)
Died of other disease 12 (8.5) 3 (4.3) 9 (12.9) NS
Recurrence 35 (25.0) 30 (42.9) 5(7.1) <0.0001 8.25 (3.19-21.31)
SNB+ = Sentinel node positive patients of the cohort. SNB- = Sentinel node negative patients of the cohort. NS = not significant. HR (95%CI) = Hazard ratio, 95%
confidence interval.
https://doi.org/10.1371/journal.pone.0216043.t001
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In the superficially spreading melanoma subgroup, there were no significant differences
between SNB+ and SNB- melanomas regarding ulceration, mitotic count and Breslow thick-
ness. However, there was a strong correlation between sentinel node positivity and decreased
OS (p = 0.005), MS (0.004) and RFS (p<0.0001). In this subgroup, high mitotic count corre-
lated with OS (p = 0.047), MSS (p = 0.019) and RFS (p = 0.020). Clinical and histopathological
parameters of this subgroup are shown in Table 3.
We further subjected sentinel node positivity to multivariate analysis of RFS, MSS and OS,
together with dichotomized Breslow thickness (<1.95mm or�2.0mm), presence of ulceration
and number of mitoses. SNB status remained as a significant independent prognostic factor
for RFS (p<0.0001), MSS (p<0.004) and OS (p = 0.003).
While BRAF V600E immunoreactivity correlated with sentinel node positivity, we found
no correlation with RFS, MSS or OS in the entire cohort. However, when evaluated in the
superficially spreading melanoma subgroup, BRAF V600E positivity indicated adverse RFS
(p = 0.039) and OS (p = 0.012). We found no association between the intensity of FMNL2
immunoreactivity and RFS, MSS or OS. Neither was FMNL2 intensity correlative in the super-
ficially-spreading melanoma subgroup. Similarly, ezrin-staining intensity did not predict RFS,
MSS or OS in the patient cohort (Table 2).
Finally, we wanted to test, whether BRAF status (BRAF V600E IHC positive or BRAF
V600E negative), in combination with clinical features (Breslow� 2mm or<2mm and mitotic
count� 1/mm2 or <1/mm2) predicts SNB status and survival in the superficially spreading
melanomas. Of the 71 patients, eleven qualified into a high risk group (all three features unfa-
vorable) and eleven into a low-risk group (all three features favorable). In the high risk-group,
SNB positivity was more common (72,7% vs. 18,2% p = 0.001) and recurrence significantly
more frequent (54,5% vs. 0,0%, p = 0.003) than in low risk group. The 5-year melanoma-spe-
cific survival in the high-risk group was only 63,6%, which was significantly different from the
low risk group, in which all patients were alive (p = 0.031). These two groups are shown in
Table 4. Melanoma-specific survival functions are shown in Fig 3.
Table 2. BRAF, FMNL2 and Ezrin staining intensities of the whole cohort.
N Whole cohort SNB + SNB - p-value HR (95%CI)
140 70 70
BRAF-status
+ 59(42.1%) 37 (52.9%) 22 (31.4%) 0.013 1.82 (1.14-2.92)
- 81(57.9%) 33 (47.1%) 48 (68.6%) 0.013
FMNL-2 status
0 (negative) - - -
1 (weak) 14(10%) 7 (10%) 7 (10%) NS
2 (intermediate) 66(47.1%) 29 (41.4%) 37 (52.9%) NS
3 (Strong) 60(42.9%) 34 (48.6%) 26 (37.1%) NS
Ezrin status
0 (negative) 5(3.6%) - 5 (7.1%) NS
1 (weak) 67(47.9%) 39 (55.7%) 28 (40.0%) NS
2 (intermediate) 56(40%) 25 (35.7%) 31 (44.3%) NS
3 (Strong) 12(8.5%) 6 (8.6%) 6 (8.6%) NS
Note that positive BRAF V600E immunoreactivity correlated with sentinel node involvement (p = 0.010). SNB+ = Sentinel node positive patients of the cohort. SNB- =
Sentinel node negative patients of the cohort, NS = not significant, HR(95%CI) = Hazard ratio, 95% confidence interval.
https://doi.org/10.1371/journal.pone.0216043.t002
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Fig 2. Kaplan-Meier analysis of intermediate thickness melanomas for recurrence free survival (RFS), melanoma
specific survival (MSS) and overall survival (OS) in the whole cohort. (A) = RFS (p<0.0001). (B) = MSS (p<0.0001).
(C) = OS (p = 0.025).
https://doi.org/10.1371/journal.pone.0216043.g002
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Discussion
Sentinel node biopsy provides important information for melanoma staging and for adjuvant
treatment decisions. However, the current practice for selecting individuals for SNB is far
Table 3. Clinical and histopathological parameters of the Superficial Spreading Melanoma—subgroup.
N SSM - group SNB + SNB- p-value HR (95%CI)
71 33 38
Age (years)
Mean 57.9 57 57
Follow-up (years)
Mean 5.1 5.3 5.3
Gender N (%)
Female 32 (45.1) 14 (42.4) 18 (47.4)
Male 39 (54.9) 19 (57.6) 20 (52.6
Location
Trunk 33 (46.5) 16 (48.5) 10 (26.3)
Lower Limb 20 (28.2) 7 (21.1) 17 (44.7)
Upper Limb 11 (15.5) 5 (15.2) 8 (21.1)
Head and neck 7 (9.8) 5 (15.2) 3 (7.9)
Breslow thickness
� 1mm 11 (15.5) 4 (12.1) 7 (18.5) NS
1.01-2.0 mm 34 (47.9) 18 (54.6) 20 (52.6) NS
2.01-4.0 mm 26 (36.6) 11 (33.3) 11 (28.9) NS
Ulceration
Absent 58 (81.7) 25 (75.8) 33 (86.8) NS
Present 13 (18.3) 8 (24.2) 5 (13.2) NS
Dermal mitoses
<1/mm2 18 (25.4) 6 (18.2) 14 (36.8) NS
�1/mm2 53 (74.6) 27 (81.8) 24 (63.2) NS
Outcome
Alive 54 (76.1) 21 (63.6) 35 (92.1) 0.005 6.30 (1.77-22.47)
Died of melanoma 14 (19.7) 12 (36.4) 2 (5.3) 0.004 9.25 (2.06-41.57)
Died of other disease 3 (4.2) 0 1 (2.6) NS
Recurrence 20 (28,2) 17(51,5) 3 (12.7) <0.0001 9.44 (2.76-32.35)
SSM-group = superficial spreading melanoma-group. SNB+ = Sentinel node positive patients of the subgroup. SNB- = Sentinel node negative patients of the subgroup.
NS = not significant. HR (95%CI) = Hazard ratio, 95% confidence interval.
https://doi.org/10.1371/journal.pone.0216043.t003






SNB+ (%) 8 (72.7%) 2 (18.2%)
Recurrence (%) 6 (54.5%) 0 (0.0%)
Melanoma survival 7 (63.6%) 11 (100%)
SNB+ = Number of sentinel node positive patients in the two groups. Recurrence = Number of recurrent melanomas
in the two groups.
https://doi.org/10.1371/journal.pone.0216043.t004
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from optimal, since only 20–25% of biopsied patients actually demonstrate lymph node involve-
ment. In this study we wanted to test whether clinicopathological parameters or novel biomark-
ers, either alone or in combination, could indicate the probability of sentinel node involvement
and thereby improve the selection of patients for SNB. In a matched case–control setting we
demonstrate that mitotic count and BRAF V600E immunohistochemistry significantly correlate
with SNB positivity in cutaneous melanomas of intermediate thickness. Our study also shows
that in this matched cohort, SNB involvement is a strong independent predictor of RFS, MSS
and OS. Finally, we show preliminary evidence that a combination of Breslow thickness, mitotic
count and BRAF immunohistochemistry may identify a group within superficial spreading mel-
anomas with an improved survival probability independent of SNB analysis.
To the best of our knowledge, this is the first report to show an association between BRAF
V600E immunohistochemistry and sentinel lymph node involvement. Until now, BRAF analy-
sis has typically been performed as part of clinical practice to find out, whether a patient would
benefit from targeted inhibition of mutant BRAF. Some studies have also linked BRAF muta-
tion with aggressive features [23]. In comparison with patients without BRAF mutations,
BRAF-mutated melanomas are more likely to metastasize to the brain and may have a worse
outcome. Our findings are in line with a recent study by Adler et al., in which BRAF mutation
was associated with lymph node metastasis and sentinel lymph node positivity [24]. The major
difference between our study and that of Adler et al. is the methodology for BRAF analysis.
Here we used an immunohistochemical detection of mutant BRAF V600E instead of DNA
sequencing used in the previous work. While the concordance between DNA sequencing and
immunohistochemistry is excellent (20), both methods have their advantages. DNA analysis
covers all BRAF variants, while the antibody is specific to BRAF V600E, and will not detect the
rare additional oncogenic mutations. Especially elder patients with head and neck melanomas
are prone to express BRAF V600K –mutation in their melanomas [25]. This subgroup of
patients could thus prove to be a limitation for BRAF IHC usage in prognosticating melano-
mas. On the other hand, immunohistochemistry is faster, cheaper and readily available as part
Fig 3. Kaplan-Meier survival analysis of intermediate thickness melanomas of high risk–and low risk–subgroups.
High risk = Breslow� 2mm, high mitotic count [� 1/mm2] + and BRAF V600E+, low risk = Breslow<2mm, low
mitotic count, BRAF V600E-). Melanoma specific 5-year survival is significantly reduced in the High risk–group
(p = 0.011).
https://doi.org/10.1371/journal.pone.0216043.g003
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of routine pathology diagnostic arsenal. Furthermore, it can be performed on sparse specimens
containing only small amounts of melanoma cells.
In our study, BRAF V600E mutation was associated with adverse RFS and OS in the super-
ficially spreading melanomas, the histological subtype which typically harbors BRAF muta-
tions. In most previous studies, a correlation between BRAF-mutation and shorter OS has
been restricted to advanced metastatic disease, while the results in early stage melanomas have
been conflicting (reviewed in [26]). There are, however, some earlier studies to support our
finding on the predictive role for BRAF mutation also in early stage disease [27,28].
In our study FMNL2-expression was not an independent prognosticator of sentinel node
involvement or melanoma outcome in contrast to previous results [15]. There may be several
explanations for this apparent discrepancy. The cohorts in the two studies were significantly
different, as the previous study included only lymph node negative cases, while in the current
study half of the patients had sentinel node involvement. Moreover, here we excluded Breslow
>4.0 mm melanomas, while in the previous study 20.1% of melanomas belonged to that
group. Finally, the previous study had more ulcerated melanomas than the current cohort
(43.2% vs. 18.3%). We conclude that further studies are needed to confirm the role of FMNL2
in melanoma biology. The fact that ezrin expression did not correlate with sentinel node posi-
tivity or outcome is not totally surprising, as most previous studies have linked ezrin expres-
sion to melanoma evolution, e.g. by demonstrating increased melanoma expression in
metastases as compared with the primary tumor.
Not surprisingly, sentinel node status proved to be a significant prognostic factor in our
material of intermediate thickness melanomas, both in the entire cohort and the superficially
spreading subtype. This correlation and the role of SNB-status has been substantiated in
numerous studies. Interestingly, independent of the sentinel node status, the combination of
Breslow thickness, mitotic count and BRAF immunohistochemistry defined patient groups
with highly different outcomes. A “low risk” group (Breslow <2mm, low mitotic count, BRAF
V600E-), had a 100% 5-year survival, while the survival probability for the “high risk” group
(Breslow>2mm, high mitotic count, BRAF V600E+, 18% of SSM) was just over 60%. It should
be noted that while the statistical difference between the groups was significant, the group sizes
were small. Therefore, further studies are needed to confirm, whether BRAF analysis in combi-
nation with conventional clinicopathological markers could provide meaningful outcome
information for clinical decision support.
This study confirms the central role of sentinel node biopsy in melanoma prognostication,
but the challenge of optimal stratification of patients for SNB remains. Our results demonstrate
that BRAF immunohistochemistry could be an integral part in assisting selection of patients
with intermediate thickness melanomas for sentinel node dissection. Further prospective stud-
ies are needed for validation of these findings.
Supporting information
S1 Table. Clinical features and staining results of individual tumors.
(XLSX)
Acknowledgments
We thank Mia Kero at HUSLAB, for help in BRAF stainings. The personnel of Genome Biol-
ogy Unit in Biocenter Finland are thanked for expertise and help with scanning of the IHC
slides. This work was supported by grants from Helsinki University research funds, Helsinki
University Hospital research funds for plastic surgery and Finska Läkaresällskapet.
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